부산대학교 도서관

Wang, T.; Jiang, H.; Lv, G.; Yu, Q.; Guan, S.

IEEE Transactions on Electromagnetic Compatibility IEEE Trans. Electromagn. Compat. Electromagnetic Compatibility, IEEE Transactions on. 65(3):870-878 Jun, 2023

Lung Cancer. 14(1):164-164

Coleman N; Trinity College Dublin Dublin Ireland.; Wei Z; Dana-Farber Cancer Institute Boston, MA United States.; Iafrate AJ; Massachusetts General Hospital Boston, MA United States.; Zwiebel JA; National Cancer Institute Bethesda, MD United States.; Sharon E; Dana-Farber Cancer Institute Boston, MA United States.; Gray RJ; Dana-Farber Cancer Institute Boston, MA United States.; Wang V; Dana-Farber Cancer Institute United States.; McShane LM; National Institutes of Health Bethesda, MD United States.; Rubinstein LV; National Institutes of Health, National Cancer Institute Bethesda, MD United States.; Patton DR; National Cancer Institute Bethesda, MD United States.; Williams PM; Frederick National Laboratory for Cancer Research United States.; Hamilton SR; City Of Hope National Medical Center Irwindale, California United States.; Takebe N; OU Health Stephenson Cancer Center Oklahoma City, Oklahoma United States.; Williams T; St. Luke's Mountain States Tumor Institute Boise, ID United States.; Croley JJ; Saint Joseph Hospital East United States.; Onitilo AA; Wisconsin NCORP Weston, Wisconsin United States.; Tricoli JV; National Cancer Institute Rockville, MD United States.; Cheng J; Broad Institute United States.; Karlovich C; Frederick National Laboratory for Cancer Research Frederick, MD United States.; Conley BA; National Cancer Institute Northport, MI United States.; Arteaga CL; The University of Texas Southwestern Medical Center Dallas, Texas United States.; Harris L; National Cancer Institute Rockville, MD United States.; O'Dwyer PJ; University of Pennsylvania Philadelphia, PA United States.; Hong DS; The University of Texas MD Anderson Cancer Center Houston, Texas United States.; Chen AP; National Cancer Institute Bethesda, MD United States.; Flaherty KT; Massachusetts General Hospital Cancer Center Boston, MA United States.

Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Salama AKS; Duke University, Durham, NC.; Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistical Center, Boston, MA.; Macrae ER; Columbus Oncology and Hematology Associates, Columbus, OH.; Park JI; Medical College of Wisconsin, Milwaukee, WI.; Chen HX; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistical Center, Boston, MA.; McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Patton D; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Hamilton SR; City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, CA.; Armstrong DK; Johns Hopkins University, Baltimore, MD.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Arteaga CL; University of Texas Southwestern Medical Center, Dallas, TX.; Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA.; Chen AP; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, NCI, Bethesda, MD.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Evrard YA; Applied and Developmental Research Directorate (ADRD), Frederick National Laboratory for Cancer Research, Frederick, MD, United States.; Alcoser SY; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.; Mullendore M; Applied and Developmental Research Directorate (ADRD), Frederick National Laboratory for Cancer Research, Frederick, MD, United States.; Chen L; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, United States.; Lih CJ; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, United States.; Kannan VR; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, United States.; Datta V; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, United States.; Dutko L; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, United States.; Jiwani S; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, United States.; Rubinstein LV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.; Zhao Y; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.; Williams PM; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, United States.; Palmisano A; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.; General Dynamics Information Technology (GDIT), Falls Church, VA, United States.; Kuhlmann L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.; Simpson M; Applied and Developmental Research Directorate (ADRD), Frederick National Laboratory for Cancer Research, Frederick, MD, United States.; Kummar S; Division of Hematology/Medical Oncology, School of Medicine, Oregon Health & Science University, Portland, OR, United States.; Das B; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, United States.; Karlovich C; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, United States.; Polley E; Department of Public Health Sciences, University of Chicago, Chicago, IL, United States.; Li MC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.; Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.; Hollingshead MG; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.; Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.; Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.

Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Ahmed J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA.; O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA.; Rubinstein LV; Biometric Research Program, National Cancer Institute Division of Cancer Treatment and Diagnosis, Bethesda, Maryland, USA.; Shin SJ; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA.; Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA.; Bruns A; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Augustine B; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Mukherjee J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Ma N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Fino K; Clinical Pharmacodynamic Biomarkers Program, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.; Fung KL; Clinical Pharmacodynamic Biomarkers Program, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.; Ferry-Galow KV; Clinical Pharmacodynamic Biomarkers Program, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.; Johnson BC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Parchment RE; Clinical Pharmacodynamic Biomarkers Program, National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.; Streicher H; National Cancer Institute Cancer Therapy Evaluation Program, Bethesda, Maryland, USA.; Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.; Center for Cancer Research, National Cancer Instiute, Bethesda, Maryland, USA.; Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA chenali@mail.nih.gov.

Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

McCourt CK; Washington University School of Medicine, St. Louis, Missouri.; Wei Z; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts.; Kalinsky K; Winship Cancer Institute at Emory University, Atlanta, Georgia.; Gray R; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts.; Wang V; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts.; McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, Maryland.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, Maryland.; Hamilton SR; City of Hope National Medical Center, Duarte, California.; Force J; Duke University Medical Center, Durham, North Carolina.; Pakanati A; Kaiser Permanente - Panorama City, Panorama City, California.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Arteaga C; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas.; Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, Pennsylvania.; Chen AP; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Tsao AS; The University of Texas MD Anderson Cancer Center, Houston, TX.; Song Z; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Ho AL; Memorial Sloan Kettering Cancer Center, New York, NY.; Mehnert JM; Laura and Issac Perlmutter Cancer Center, New York, NY.; Ivy P; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Gray RJ; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Wang V; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; McShane LM; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Rockville, MD.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Hamilton SR; City of Hope National Medical Center, Duarte, CA.; Takebe N; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Ajumally R; University of Oklahoma Health Science Center, Oklahoma City, OK.; Silhavy J; Illumina, Inc, San Diego, CA.; Rahmanian S; Illumina, Inc, San Diego, CA.; Das B; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD.; Chen L; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD.; Karlovich C; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD.; Lococo JS; Illumina, Inc, San Diego, CA.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Arteaga CL; University of TX Southwestern Medical Center, Dallas, TX.; Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; O'Dwyer PJ; University of Pennsylvania, Pennsylvania Hospital, Philadelphia, PA.; Chen AP; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, Bethesda, MD.; Flaherty KT; Massachusetts General Hospital, Boston, MA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Rini BI; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.; Best AF; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Bowman MD; The Emmes Company LLC, Rockville, Maryland.; Mishkin GE; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Denicoff AM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Harris L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Geiger AM; National Cancer Institute Center for Strategic Scientific Initiatives, Rockville, Maryland.; Mark NM; Swedish Medical Center, Seattle, Washington.; Pergam SA; Fred Hutchinson Cancer Center, Seattle, Washington.; Warner JL; Warren Alpert Medical School of Brown University, Providence, Rhode Island.; Department of Biostatistics, School of Public Health, Brown University, Providence, Rhode Island.; Khorana AA; Cleveland Clinic, Cleveland, Ohio.; Gnjatic S; Icahn School of Medicine at Mount Sinai, New York, New York.; Yen TWF; Medical College of Wisconsin, Milwaukee.; Liles DK; East Carolina University Brody School of Medicine, Greenville, North Carolina.; Bestvina CM; Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois.; Shah NJ; Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.; Norrell JT; Rutgers Cancer Institute of New Jersey, New Brunswick.; Hershman DL; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.; Holter-Chakrabarty JL; University of Oklahoma College of Medicine, Oklahoma City.; Poklepovic AS; Virginia Commonwealth University Massey Cancer Center, Richmond.; Chanock SJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.; Sankaran H; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Korde LA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.

Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

Janku F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.; Jegede OA; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA.; Puhalla SL; University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA.; Konstantinopoulos PA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA.; Meric-Bernstam F; Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.; Zwiebel JA; Division of Cancer Treatment and Diagnosis, Investigational Drug Branch, National Cancer Institute, Bethesda, MD.; Gray RJ; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA.; Wang XV; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA.; McShane LM; Division of Cancer Treatment and Diagnosis, Biometric Research Program, National Cancer Institute, Bethesda, MD.; Rubinstein LV; Division of Cancer Treatment and Diagnosis, Biometric Research Program, National Cancer Institute, Bethesda, MD.; Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Hamilton SR; City of Hope National Medical Center, Duarte, CA.; Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Ghani S; University of Oklahoma Health Science Center, Oklahoma City, OK.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.; Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA.; Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.; Rubinstein LV; Biometric Research Program, NCI, NIH, Bethesda, MD, USA.; Wilsker D; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.; Moore N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Hogu M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Piekarz R; Cancer Therapeutics Evaluation Program, NCI, NIH, Bethesda, MD, USA.; Covey J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Beumer JH; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Ferry-Galow KV; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.; Villaruz LC; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Hollingshead MG; Biological Testing Branch, NCI, NIH, Frederick, MD, USA.; Holleran JL; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Deppas JJ; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Pommier Y; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.; Ko B; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Johnson BC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Parchhment RE; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.; Ivy P; Cancer Therapeutics Evaluation Program, NCI, NIH, Bethesda, MD, USA.; Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.; Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA. chenali@mail.nih.gov.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Wei Z; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.; Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Davies MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Gray RJ; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.; Wang V; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.; McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Hamilton SR; City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, CA.; Liu R; Department of Hematology Oncology, The Permanente Medical Group, San Francisco, CA.; Bota DA; UCI Health Chao Family Comprehensive Cancer Center, Orange, CA.; Swiecicki PL; University of Michigan Rogel Cancer Center, Ann Arbor, MI.; Buchschacher GL; Kaiser Permanente Southern California, Los Angeles, CA.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Conley BA; UT Southwestern Simmons Cancer Center, Dallas, TX.; Arteaga CL; UT Southwestern Simmons Cancer Center, Dallas, TX.; Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA.; Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

O'Hara MH; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania.; Jegede O; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts.; Dickson MA; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.; DeMichele AM; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania.; Piekarz R; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Gray RJ; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts.; Wang V; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts.; McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Patton DR; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, Maryland.; Hamilton SR; City of Hope National Medical Center, Duarte, California.; Onitilo A; Marshfield Medical Center - Weston, Weston, Wisconsin.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Arteaga CL; UT Southwestern Simmons Cancer Center, Dallas, Texas.; Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; O'Dwyer PJ; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania.; Chen AP; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, Bethesda, Maryland.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Gross AM; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. andrea.gross@nih.gov.; O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Dombi E; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Tibery C; Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.; Herrick WG; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.; Martin S; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Angus SP; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health and Herman B. Wells Center for Pediatric Research, Indianapolis, IN, USA.; Shern JF; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Rhodes SD; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health and Herman B. Wells Center for Pediatric Research, Indianapolis, IN, USA.; Foster JC; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Baldwin A; Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.; Davis C; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health and Herman B. Wells Center for Pediatric Research, Indianapolis, IN, USA.; Dixon SAH; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health and Herman B. Wells Center for Pediatric Research, Indianapolis, IN, USA.; Fagan M; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Ong MJ; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Wolters PL; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Tamula MA; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Reid O; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Sankaran H; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Fang F; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health and Herman B. Wells Center for Pediatric Research, Indianapolis, IN, USA.; Govindharajulu JP; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.; Browne AT; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Kaplan RN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Heisey K; Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.; On TJ; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Xuei X; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health and Herman B. Wells Center for Pediatric Research, Indianapolis, IN, USA.; Zhang X; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Johnson BC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Parchment RE; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.; Clapp DW; Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health and Herman B. Wells Center for Pediatric Research, Indianapolis, IN, USA.; Srivastava AK; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.; Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Widemann BC; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. widemanb@mail.nih.gov.

Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

Gien LT; Odette Cancer Centre-Sunnybrook Health Sciences Centre, Toronto, ON, Canada.; Song Z; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.; Poklepovic A; Virginia Commonwealth University/Massey Cancer Center, Richmond, VA.; Collisson EA; Fred Hutchinson Cancer Center, Seattle, WA.; Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Gray RJ; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.; Wang V; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.; McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Deceased.; Hamilton SR; City of Hope National Medical Center, Duarte, CA.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.; Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA.; Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Flaherty KT; Massachusetts General Hospital Cancer Center; Boston, MA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Zauderer MG; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY and Westchester Medical Center and New York Medical College, Valhalla, NY.; Jegede O; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Jackman DM; Dana Farber Cancer Institute, Boston, MA.; Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Patton DR; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Hamilton SR; City of Hope National Medical Center, Duarte, CA.; Takebe N; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Huang R; Brigham and Women's Hospital, Boston, MA.; Carrillo JA; University of California, Irvine, CA.; Brenner AJ; University of Texas Health Sciences Center, San Antonio, TX.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.; Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA.; Chen AP; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Chen MF; Memorial Sloan Kettering Cancer Center, New York, NY.; Song Z; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Yu HA; Memorial Sloan Kettering Cancer Center, New York, NY.; Sequist LV; Massachusetts General Hospital Cancer Center, Boston, MA.; Lovly CM; Vanderbilt-Ingram Cancer Center, Nashville, TN.; Mitchell EP; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA.; Moscow JA; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Hamilton SR; City of Hope National Medical Center, Duarte, CA.; Umemura Y; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.; Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA.; Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Gettinger SN; Yale University, New Haven, CT.; Song Z; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Reckamp KL; Cedars Sinai Medical Center, Los Angeles, CA.; Moscow JA; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Gray RJ; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Hamilton SR; City of Hope National Medical Center, Duarte, CA.; Kong XT; UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, CA.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.; Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA.; Chen AP; Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

Mansfield AS; Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Mansfield.aaron@mayo.edu.; Wei Z; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA.; Mehra R; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.; Shaw AT; Massachusetts General Hospital, Boston, MA, USA.; Lieu CH; University of Colorado Cancer Center, Aurora, CO, USA.; Forde PM; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.; Drilon AE; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.; Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, PA, USA.; Wright JJ; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.; Takebe N; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.; Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.; Hovelson D; Strata Oncology, Inc, Ann Arbor, MI, USA.; Tomlins S; Strata Oncology, Inc, Ann Arbor, MI, USA.; Zeng J; Caris Life Sciences, Irving, TX, USA.; Poorman K; Caris Life Sciences, Irving, TX, USA.; Malik N; Tempus, Chicago, IL, USA.; Gray RJ; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA.; Li S; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA, USA.; McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.; Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.; Patton D; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD, USA.; Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD, USA.; Hamilton SR; City of Hope, Duarte, CA, USA.; Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.; Arteaga CL; Simmons Cancer Center, University of Texas Southwestern, Dallas, TX, USA.; Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA, USA.; Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.; Flaherty KT; Massachusetts General Hospital, Boston, MA, USA.

Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE

Gong J; Cedars-Sinai Medical Center, Los Angeles, CA.; Mita AC; Cedars-Sinai Medical Center, Los Angeles, CA.; Wei Z; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Cheng HH; University of Washington, Seattle, WA.; Mitchell EP; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA.; Wright JJ; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Ivy SP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; Gray RC; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.; McShane LM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Rubinstein LV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Patton DR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Williams PM; Frederick National Laboratory for Cancer Research, Bethesda, MD.; Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA.; Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.; Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA.; Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE